These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 21537162

  • 1. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
    Zangari M, Berno T, Zhan F, Boucher KM, Tricot G, Fink L.
    Blood Coagul Fibrinolysis; 2011 Jul; 22(5):420-3. PubMed ID: 21537162
    [Abstract] [Full Text] [Related]

  • 2. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
    Schöni R, Quehenberger P, Wu JR, Wilmer M.
    Thromb Res; 2007 Jul; 119(1):17-26. PubMed ID: 16934314
    [Abstract] [Full Text] [Related]

  • 3. Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay.
    Gardiner C, Cohen H, Jenkins A, Machin SJ, Mackie IJ.
    Blood Coagul Fibrinolysis; 2006 Sep; 17(6):477-83. PubMed ID: 16905952
    [Abstract] [Full Text] [Related]

  • 4. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G, Valverde S.
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Detecting APC-resistant factor V: a functional method without plasma dilution.
    Rylatt DB, Hohnen-Behrens C, Pilgrim RL, Dickeson LE, Neal M, Exner T.
    Blood Coagul Fibrinolysis; 1999 Sep; 10(6):359-66. PubMed ID: 10493217
    [Abstract] [Full Text] [Related]

  • 8. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J, Thomassen MC, Rimmer J, Hamulyak K, van der Meer J, Tans G, Preston FE, Rosing J.
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [Abstract] [Full Text] [Related]

  • 9. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
    De Mitrio V, Marino R, Scaraggi FA, Di Bari L, Giannoccaro F, Petronelli M, Ranieri P, Tannoia N, Schiraldi O.
    Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
    [Abstract] [Full Text] [Related]

  • 10. Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
    Sonnevi K, Tchaikovski SN, Holmström M, Rosing J, Bremme K, Lärfars G.
    Thromb Haemost; 2011 Nov; 106(5):901-7. PubMed ID: 21947267
    [Abstract] [Full Text] [Related]

  • 11. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter C.
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [Abstract] [Full Text] [Related]

  • 12. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL, Welsh CH, Qamar Z, Marlar RA.
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [Abstract] [Full Text] [Related]

  • 13. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
    Strandberg K, Svensson PJ, Ohlin AK.
    Thromb Res; 2007 Jan; 121(2):145-51. PubMed ID: 17499343
    [Abstract] [Full Text] [Related]

  • 14. Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
    Crowley MP, Kevane B, O'Shea SI, Quinn S, Egan K, Gilligan OM, Ní Áinle F.
    Clin Appl Thromb Hemost; 2016 Sep; 22(6):554-62. PubMed ID: 26759370
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.
    Kristinsson SY, Björkholm M, Schulman S, Landgren O.
    Semin Hematol; 2011 Jan; 48(1):46-54. PubMed ID: 21232658
    [Abstract] [Full Text] [Related]

  • 17. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy].
    Magdelaine A, Soubrier F, Berkane N, Uzan S, Verdy E.
    Ann Biol Clin (Paris); 1998 Jan; 56(4):445-50. PubMed ID: 9754280
    [Abstract] [Full Text] [Related]

  • 18. Haemostatic changes and acquired activated protein C resistance in normal pregnancy.
    Mahieu B, Jacobs N, Mahieu S, Naelaerts K, Vertessen F, Weyler J, Jacquemyn Y, Van der Planken M.
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):685-8. PubMed ID: 17890957
    [Abstract] [Full Text] [Related]

  • 19. Acquired activated protein C resistance is associated with IgG antibodies to protein S in patients with systemic lupus erythematosus.
    Nojima J, Iwatani Y, Ichihara K, Tsuneoka H, Ishikawa T, Yanagihara M, Takano T, Hidaka Y.
    Thromb Res; 2009 May; 124(1):127-31. PubMed ID: 19128822
    [Abstract] [Full Text] [Related]

  • 20. Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
    Chaireti R, Jennersjö C, Lindahl TL.
    Thromb Res; 2009 Jun; 124(2):178-84. PubMed ID: 19232683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.